DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Phase 2

Recruiting

Conditions: Heart Failure

Interventions: Other: Placebo
Drug: BMS-986435

First Posted Date: 2023-11-08

Last Posted Date: 2025-05-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 198

Registration Number: NCT06122779

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Local Institution - 0096, Lakewood, Colorado, United States
🇺🇸
Local Institution - 0077, Jacksonville, Florida, United States

and more 104 locations

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 4

Recruiting

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: Mavacamten

First Posted Date: 2023-11-01

Last Posted Date: 2025-05-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 85

Registration Number: NCT06112743

Locations: 🇮🇹
Local Institution - 0056, Pavia, Lombardia, Italy
🇺🇸
Cedars Sinai Medical Center - 1207 San Vicente Blvd, Los Angeles, California, United States
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States

and more 86 locations

A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: Deucravacitinib

First Posted Date: 2023-10-27

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 550

Registration Number: NCT06104644

Locations: 🇩🇪
Dermatologische Spezial- und Schwerpunktpraxis Selters, Selters, Rhineland-Palatinate, Germany
🇩🇪
Company for Medical Study & Service Selters, Selters, Germany

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: nivolumab
Drug: relatlimab+nivolumab
Drug: nivolumab+rHuPH20
Drug: relatlimab+nivolumab+rHuPH20

First Posted Date: 2023-10-26

Last Posted Date: 2025-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT06101134

Locations: 🇺🇸
Local Institution - 0036, Issaquah, Washington, United States
🇺🇸
Local Institution - 0030, Seattle, Washington, United States
🇬🇷
Local Institution - 0019, Thessaloniki, B, Greece

and more 28 locations

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: NSCLC

Interventions: Drug: BMS-986315
Drug: Nivolumab
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2023-10-23

Last Posted Date: 2025-04-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1

Registration Number: NCT06094296

Locations: 🇺🇸
Local Institution - 0058, Boise, Idaho, United States
🇺🇸
Local Institution - 0044, Clermont, Florida, United States
🇺🇸
Local Institution - 0049, Houston, Texas, United States

and more 5 locations

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

Phase 1

Recruiting

Conditions: Relapsed/Refractory Non-Hodgkin Lymphoma

Interventions: Drug: BMS-986458
Drug: Rituximab

First Posted Date: 2023-10-19

Last Posted Date: 2024-08-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 273

Registration Number: NCT06090539

Locations: 🇩🇪
Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 19 locations

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

Phase 1

Completed

Conditions: Healthy Male Participants

Interventions: Drug: BMS-986322

First Posted Date: 2023-10-18

Last Posted Date: 2024-03-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT06088264

Locations: 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Other: Placebo
Drug: BMS-986454

First Posted Date: 2023-10-17

Last Posted Date: 2025-03-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 63

Registration Number: NCT06086886

Locations: 🇬🇧
Local Institution - 0001, Nottingham, United Kingdom
🇬🇧
Local Institution - 0002, London, Greater London, United Kingdom

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Other: Placebo
Drug: BMS-986446

First Posted Date: 2023-10-16

Last Posted Date: 2024-03-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT06084598

Locations: 🇺🇸
Local Institution - 0001, Cypress, California, United States

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

Recruiting

Conditions: Myelodysplastic Syndrome
Beta Thalassemia

Interventions: Drug: Luspatercept

First Posted Date: 2023-10-10

Last Posted Date: 2024-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 104

Registration Number: NCT06073860

Locations: 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷
Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy